Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


06. January 2021 | 07:57 CET

Amazon, dynaCERT, Pfizer: Innovation thanks to proven ideas

  • Investments
Photo credits: pixabay.com

Individual stocks in the stock market are valued based on future earnings potential, which results in high demand for companies poised for growth. The most recent examples are hydrogen stocks, such as NEL and Plug Power. Gold has also been experiencing a renaissance since the pandemic's outbreak and is poised to climb to new heights in the first trading days of 2021. However, good returns can also be achieved with supposedly established stocks. Although ordering from Amazon is as obvious to many of us as going to the nearest supermarket, the Company still has excellent growth potential.

time to read: 3 minutes by Nico Popp


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Amazon: Growth at a high level

Amazon has long been more than just a retailer on the web. In addition to ordering almost any product via the platform, Amazon also offers services and is a media company. With inexpensive tablets and the streaming offer Prime Video, the former bookseller has made it into many living rooms. In the meantime, even the Bundesliga soccer league is flickering across the in-house streaming platform. Traditional online retailing has become even more popular as a result of the pandemic. Many older people ventured online for the first time in March 2020, placed orders and had good experiences. Amazon, in particular, as the top dog with accommodating warranty processing, is likely to benefit from the growing popularity of older generations.

While traditional retailers had to lay off staff and suffered from the pandemic restrictions, Amazon hired a whole 400,000 new people last year. This contrast emphasizes how well-positioned Amazon is. The numbers are right, too. In the third quarter of 2020 alone, Amazon made a profit of USD 6.3 billion. That's already the next record after the quarter before. The stock has gained more than 50% on a one-year horizon and is also already ambitiously valued. Amazon remains a stable value. Ten years from now, Amazon will still be making healthy sales - and it remains to be seen how many traditional retailers will fare by then.

dynaCERT: Hydrogen Catalysts and Software for the Traffic Turnaround

The Canadian Company dynaCERT is also reaching for the stars. Its goal is to make existing vehicle fleets more sustainable. To this end, dynaCERT has developed an electrolysis unit with hydrogen technology that can be used primarily in large diesel engines and is said to optimize combustion by up to 19%. In recent months, some US municipalities have stepped in and converted their public transport systems. Public authorities, in particular, are under pressure to pursue sustainable solutions while keeping costs down. Compared to buses with electric motors, the purchase of a HydraGEN retrofit unit can pay for itself within 12 months, according to the manufacturer.

In addition to its catalysts, dynaCERT is also active in the field of telematics software. The aim is to measure savings and use the wealth of data to improve the environmental balance sheet further. Thanks to the savings documentation, fleet operators can receive credits in the form of CO2 certificates that are publicly traded. These CO2 certificates create a further incentive to use dynaCERT's solutions. In German trading, the share was able to stabilize just below EUR 0.40 and recently indicated breakouts several times. Speculative investors can add the stock to their watchlist.

Pfizer: Blockbusters secure the dividend

The Pfizer share also shows that share price gains and innovations do not necessarily have to come from startups with revolutionary technology. Although the pharmaceutical giant is cooperating with the Mainz-based Company BioNTech in producing the Covid-19 vaccine and is relying on the new mRNA technology, Pfizer also offers a lot of classic "bread-and-butter" business. In total, Pfizer has ten blockbuster drugs on offer, each of which generates more than USD 1 billion in sales. Pfizer has spun off its generics and consumer products business into a joint venture with GlaxoSmithKline and focuses only on high-margin drugs. In this way, Pfizer hopes to build on Viagra, Lipitor, and other former blockbusters' successes.

This change in strategy has not yet gone down well on the stock market: Over a one-year period, the share price fell by 13.8% despite the vaccine hype. The value also shows a slight downward trend over a three-year period. However, Pfizer's dividend is the primary driver of returns: The Company recently announced its 328th consecutive quarterly dividend. The dividend yield is thus stable at over 4%. That is probably another reason why investor legend Warren Buffett has recently invested heavily in pharmaceutical stocks and has also bought Pfizer. Those who are not too bored by the leisurely share price development will find Pfizer a stable long-term pillar for their portfolio.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read